Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for non-ocular Behçet's syndrome
ISRCTN94958652Phase 2Completed
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Behçet's disease (BD) comparing Secukinumab with Placebo then secukinumab (2 arms). Primary endpoint: Change from baseline in Behçet's oral ulcer severity score at week 16. Started Apr 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on ISRCTN94958652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94958652.